TC Biopharm (TCBP) Provides Update on Acquisition Strategy and Current Targets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St indexes climb after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
TCBP Provides Update on Acquisition Strategy and Current Targets
December 31, 2024 10:15 AM ESTEDINBURGH, Scotland, Dec. 31, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP)Â a clinical-stage biotechnology company developing platform allogeneic gamma-delta T-cell therapies for cancer and other indications, today announced it has advanced negotiations with both of its previously aforementioned acquisition candidates.
... More
